Novel agents in development for advanced non-small cell lung cancer by Thomas E. Stinchcombe

Get full text

Current management of rearranged non-small cell lung cancer by Thomas E Stinchcombe

Get full text

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort by Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy

Get full text

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial by Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD

Get full text

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400... by Roy S Herbst, Naiyer Rizvi, Karen Kelly, Vassiliki A Papadimitrakopoulou, Natasha B Leighl, Mary W Redman, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, James L Wade, William J Irvin, Sreekanth C Reddy, Jeffrey Crawford, Jeffrey D Bradley, Thomas E Stinchcombe, Suresh S Ramalingam, Jieling Miao, Katherine Minichiello, David R Gandara

Get full text

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastati... by Thomas A. Hensing, MD, MS, Xiaofei Wang, PhD, Thomas E. Stinchcombe, MD, Junheng Gao, MS, Michael V. Knopp, MD, PhD, Mark Watson, MD, PhD, Arkadiusz Z. Dudek, MD, PhD, Stephen L. Graziano, MD, Jyoti D. Patel, MD, Bryan A. Faller, MD, Konstantin H. Dragnev, MD, David Kozono, MD, PhD, Everett E. Vokes, MD

Get full text